Ivonescimab Plus Chemotherapy Extends PFS vs PD-1 Control in Squamous NSCLC
In the phase 3 HARMONi-6 trial, the bispecific antibody ivonescimab [...]
Oncology
Ivonescimab Plus Chemotherapy Extends PFS vs PD-1 Control in Squamous NSCLC
| Categories: oncology
In the phase 3 HARMONi-6 trial, the bispecific antibody ivonescimab (targeting both PD-1 and VEGF) plus carboplatin/paclitaxel significantly improved progression-free survival (PFS) compared with the […]
Choosing and Sequencing Tyrosine Kinase Inhibitors for Driver-Positive NSCLC
Next-generation tyrosine kinase inhibitors (TKIs) may be reshaping treatment for [...]
NCCN NSCLC 2026: An Update on Preferred Regimens
The November 6, 2025 update to the NCCN Clinical Practice [...]
Real-World Biomarker Testing in NSCLC: Who Gets Tested and How It Varies
Lung cancer remains the leading cause of cancer death worldwide, [...]
EIK1001 Plus Chemo-Immunotherapy Achieves 64% Objective Response Rate in First-Line NSCLC
In the phase 2 TeLuRide-005 study, researchers found that adding [...]
Pulsed Low-Dose-Rate Chemoradiation Cuts Severe Esophagitis in Esophageal Cancer and NSCLC
Researchers of a single-arm phase 1 study presented at the [...]
Osimertinib Plus Local Therapy Extends Progression-Free Survival in EGFR-Mutant NSCLC
Researchers of the phase 2 NorthStar trial (NCT03410043) showed that [...]
Frontline Zongertinib Delivers 77% Objective Response Rate in HER2-Mutated NSCLC
Frontline zongertinib produced high activity in treatment-naïve, advanced HER2-mutated non-small [...]
High NMT1/TIMM17A Expression Predicts Poor LUAD Survival—Rationale for NMT Inhibitors
Advanced non-small cell lung cancer (NSCLC) treatment has shifted with [...]
CHEST Guideline: Early-Stage Non-Small Cell Lung Cancer Management
This CHEST guideline reviews primary treatment options for stage I [...]
STARS Trial 10-Year Data: SABR Noninferior to Surgery in Operable Stage I NSCLC
Researchers of the phase 2 revised STARS trial reported 10-year [...]
HER2-Mutant NSCLC: Zongertinib Shows Intracranial Activity, Receives Accelerated FDA Approval
HER2-mutant non-small cell lung cancer (NSCLC) is a rare subtype [...]
Faster Treatment Starts With Oncology Nurse Navigator and Concurrent Liquid Biopsy
Researchers of a single-center, retrospective pre/post project at the University [...]
Artificial Intelligence in Neoadjuvant Non–Small Cell Lung Cancer
Artificial intelligence (AI) paired with multiomics is beginning to deliver [...]
EGFR+ Metastatic Non–Small Cell Lung Cancer: Can Post-TKI Surgery Delay Resistance?
Researchers of a randomized phase 2 trial asked whether resecting [...]
Traditional Biomarkers Fall Short in First-Line Immunochemotherapy for EGFR/ALK– Non-Small Cell Lung Cancer
In a prospective multicenter cohort of 162 patients with advanced [...]
Video-Assisted Thoracoscopic Surgery Shown to Lower Mortality vs Open Lobectomy in Early-Stage NSCLC
Video-assisted thoracoscopic surgery (VATS) was linked to a 21% reduction [...]
STAS Tied to Worse Survival in Early-Stage NSCLC, Regardless of Surgical Approach
In a pathology review from the phase 3 JCOG0802/WJOG4607L trial, [...]
ASCO Updates Stage IV NSCLC Living Guideline
ASCO updated its living guideline for stage IV non-small cell [...]
Zongertinib: FDA Breakthrough Therapy Designation for First-Line HER2-Mutant NSCLC
The FDA granted breakthrough therapy designation to the oral HER2 [...]
Wildfire Air Pollution Linked to Higher Lung Cancer Mortality, but Spikes Show Survival Benefit
Researchers of a recent study found that higher ambient exposure [...]
IMM2510 Plus Chemotherapy Shows Promising Response in Frontline Advanced NSCLC
Researchers of a phase 2 trial, conducted in China, showed [...]
High Intake of Ultraprocessed Foods Linked to Increased Lung Cancer Risk
Authors of a recent study found that greater consumption of [...]
FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant NSCLC
The FDA has granted accelerated approval to zongertinib (Hernexeos) [...]
Wildfire Smoke Exposure Lengthens Hospital Stays for Lung Cancer Surgery Patients
A study by the American Cancer Society and Harvard T.H. [...]
Video-Based Palliative Care Offers Similar Benefits to In-Person Visits for Advanced NSCLC
Researchers of a recent study investigated the effectiveness of delivering [...]
Plasma ctDNA Kinetics Predict Survival in Advanced NSCLC: Meta-Analysis Highlights Biomarker Potential
A recent systematic review and meta-analysis demonstrated that plasma circulating [...]
Zongertinib Shows Promising Efficacy in HER2-Mutant Solid Tumors, Including NSCLC
Zongertinib, a HER2-directed tyrosine kinase inhibitor, showed promising efficacy and [...]
Young Patients With Lung Cancer Face Unique Challenges Requiring Tailored Care
Young patients diagnosed with lung cancer face unique challenges, as [...]
Study Finds Genetic Amplifications in NSCLC Linked to Reduced Survival and Fewer Driver Mutations
A recent retrospective analysis identified clinically relevant subgroups of non–small [...]
Lobectomy and Segmentectomy Linked to Better Long-Term Survival in Early-Stage NSCLC
Researchers of a recent study suggest that anatomic lung resections, [...]
Method Predicts KRAS G12C Inhibitor Effectiveness in NSCLC by Measuring RAS-RAF Interactions
Researchers have identified a novel method for predicting the effectiveness [...]
Minimal ctDNA Traces Linked to Lung Cancer Recurrence Risk
A recent study revealed that even minimal traces of circulating [...]
Study Shows Promise for LCT and Chemotherapy in Stage IV NSCLC With Oligometastases
A recent phase 2 study on local consolidative therapy (LCT) [...]
Body Composition’s Role in Non-Small Cell Lung Cancer Prognosis
A recent study highlighted the increasing incidence of lung cancer [...]
Zongertinib Shows Durable Efficacy in HER2-Mutant NSCLC With High Response and Disease Control Rates
Zongertinib has demonstrated durable efficacy in patients with pretreated advanced [...]
Study Highlights Advancements in Molecular Characterization of Endometrial Cancer
In a recent study, researchers provided an overview of the [...]
Immune Checkpoint Inhibitor-Based Therapy in Black and White Patients With Renal Cancer
Researchers of a study suggest that immune checkpoint inhibitor–based therapy [...]
Study Reveals Inadequate Reporting of Patient-Reported Outcomes in Genitourinary Cancer Trials
Researchers of a recent study highlighted a significant gap in [...]
Subcutaneous Nivolumab Shows Noninferiority in Renal Cell Carcinoma: CheckMate 67T Trial Insights
Researchers of the phase 3 CheckMate 67T trial revealed significant [...]
KEYNOTE-564: Pembrolizumab Boosts Survival in Clear Cell Renal Cell Carcinoma
The phase 3 KEYNOTE-564 study demonstrated a significant improvement in [...]
Study: End-of-Life Immunotherapy on the Rise, Especially for Advanced Cancers and Outside Academic Centers
In a retrospective cohort study, researchers utilized data from the [...]
FDA Awards Breakthrough Therapy Status to BNT323/DB-1303 for Advanced Endometrial Cancer
The FDA has granted breakthrough therapy designation to BNT323/DB-1303, a [...]
FDA Reviews PET Imaging Agent 89Zr-DFO-girentuximab for Kidney Cancer
A biologics license application has been submitted to the [...]
Phase 3 RUBY Trial Shows Dostarlimab Combination Enhances Progression-Free Survival in Advanced Endometrial Cancer
The phase 3 RUBY trial (NCT03981796) revealed that treatment with [...]
Clinical Trial Reveals Lenvatinib-Pembrolizumab Outperforms Sunitinib in Advanced Renal Cell Carcinoma
In a phase 3 clinical trial, CLEAR/KEYNOTE-581, researchers randomly assigned [...]
Modified Ipilimumab Regimen Reduces Adverse Events in Patients With Renal Cancer
A UK PRISM phase 2 trial revealed that a [...]
POD1UM-101 Trial Reveals Retifanlimab’s Efficacy in Endometrial Cancer
The phase 1 POD1UM-101 trial, presented at the 2023 [...]
Selinexor Shows Prolonged Progression Free Survival in TP53 Wild-Type Endometrial Cancer
Researchers of the phase 3 ENGOT-EN5/GOG-3055/SIENDO trial reported at the [...]
Study Confirms Safety of Durvalumab, Tremelimumab Plus Surgery in Renal Cell Carcinoma
A study presented at the 2023 Society of Urologic Oncology [...]
Study Presents Warning as Over 73% of TikTok Content on Gynecologic Cancers is Misleading or Inaccurate
Results of a recent study indicate that most TikTok content [...]
RUBY Trial: Dostarlimab Boosts Survival in Endometrial Cancer With Specific Molecular Profiles
The recent phase 3 RUBY trial showed that the addition [...]
Noninvasive Stereotactic Body Radiation Therapy Achieves 100% Local Control in Kidney Cancer
Results of the recent FASTRACK II trial showed positive results [...]
Phase 3 LIFESPARK-005 Trial: Belzutifan Outperforms Everolimus in Advanced Kidney Cancer Treatment Outcomes
Results of the recent phase 3 LIFESPARK-005 trial showed that [...]
Novel Drug Response Predictor Tool Enhances Dovitinib Treatment Efficacy Prediction in Renal Cell Carcinoma and Other Cancers
A recent study introduced and clinically validated a drug response [...]
NHANES Data Reveals Gender-Specific Links Between Environmental Chemical Exposures and Cancer
In a recent analysis, researchers utilized data from the [...]
Study Shows High Survival Rate in Patients With Kidney Cancer Using Noninvasive Stereotactic Ablative Body Radiotherapy
In a phase 2 study, Trans-Tasman Radiation Oncology Group [...]
Trastuzumab Deruxtecan Shows Promising Efficacy for Patients With HER2-Expressing Uterine Carcinosarcoma Regardless of HER2 Levels
In a recent study, researchers assessed the effectiveness and safety [...]
CLEAR Trial: Lenvatinib Plus Pembrolizumab Shows Sustained Superiority in Advanced Renal Cell Carcinoma
The phase 3 CLEAR trial, presented at the 2023 ASCO [...]
Extended Lymphadenectomy Does Not Improve Survival in Bladder Cancer Surgery, Increases Risk of Adverse Events
A study funded by the National Cancer Institute presented [...]
Blue Light Cystoscopy Improves Malignant Lesion Detection in Bladder Cancer Surveillance
Researchers presented a study at the 2023 American Urological [...]
Bladder-Sparing Trimodal Therapy Found Effective in Node-Positive Nonmetastatic Bladder Cancer
A retrospective analysis published in the Journal of Clinical [...]
Loss of Y Chromosome in Aging Men Hampers Cancer Defense and Enhances Bladder Cancer Treatment Response
A recent study facilitated by Cedars-Sinai Cancer reveals that, [...]
Male Breast Cancer Patients at Increased Risk of Heart Disease
Male breast cancer patients are at higher risk of cardiovascular [...]
Cancer Cells Hibernate to Evade Chemotherapy
To survive chemotherapy, cancer cells enter into a slow-dividing, hibernation-like [...]
GoFund Who? These Are The Cancer Patients Who Really Benefit from Crowdfunding Campaigns
While likely well-intentioned, the use of crowdfunding campaigns for cancer [...]
Lack of Health Access, Not Biology, Accounts for the Racial Disparity in Cancer Care
A new study shows that Black patients have poorer cancer [...]
African American Breast Cancer Survivors Experience Sleep-Related Disparities
African American breast cancer survivors (AABCS) experience disparities in sleep [...]